Chronic bronchitis — all decisions

The Board remands the claims for service connection for a mental health disorder, respiratory disorder, left foot disorder, left shoulder disorder, and TBI to correct pre-decisional duty to assist errors.

The Board is remanding the issue of service connection for a recurrent respiratory disability to include asthma and bronchitis claimed as the result of herbicide agent exposure due to an inadequate VA respiratory evaluation and the need for additional clinical documentation.

The appeal for service connection of chronic bronchitis was dismissed due to the Veteran's impermissible concurrent election and the June 2024 decision not being a final appealable decision.

The Board granted service connection for tongue ulcer and denied an increased initial rating in excess of 30 percent for bronchial asthma with bronchitis. The claims for higher ratings for lumbosacral strain, bilateral lower extremity radiculopathy were remanded.

The Board granted service connection for bronchitis and asthma, both related to exposure to burning waste in service.

The Board granted an effective date of August 10, 2022, for the award of service connection for bronchitis under the PACT Act.

The Board denied an earlier effective date for PTSD and major depressive disorder, denied service connection for colon polyps, type II diabetes, sinusitis, and chronic bronchitis, and granted service connection for allergic rhinitis, sleep apnea, and erectile dysfunction. Five neuropathy conditions were remanded for further development.

The Board denied service connection for tinea pedis, left wrist disability, asthmatic bronchitis, and gastroesophageal reflux disease (GERD) as the evidence did not support a finding of a causal relationship between these conditions and the Veteran's active duty service.

The Board remands the claims for service connection for asthma, bronchitis, obstructive sleep apnea, rhinitis, and sinusitis due to a pre-decisional duty to assist error.

The Board granted service connection for chronic bronchitis, finding the evidence to be in approximate balance and resolving reasonable doubt in favor of the Veteran.

The veteran withdrew all pending appeals, and the Board dismissed the appeals.

The Board remands the claim for a respiratory condition, claimed as chronic bronchitis, to ensure an adequate VA examination and obtain private treatment records.

The Board granted service connection for allergic rhinitis and denied service connection for left ear hearing loss, while dismissing the appeal for sinusitis. The claims for initial disability ratings for acute bronchitis and right knee osteoarthritis were remanded.

The Board granted service connection for rhinitis, bronchitis, and asthma based on presumed exposure to fine particulate matter or participation in TERA during service. The claim for an increased rating for chronic sinusitis was denied.

The Board granted a 30 percent rating for benign paroxysmal positional vertigo (BPPV) prior to June 12, 2024, and denied all other claims including service connection for various respiratory conditions.

The Board granted service connection for several conditions, including diabetes mellitus and peripheral neuropathy, but denied increased ratings for intervertebral disc syndrome and other conditions.

The Board denied the Veteran's claim for an initial compensable disability rating for bronchitis based on the evidence of record, which showed that his FEV-1 was 99 percent predicted and did not meet the criteria for a compensable rating.

The Board denied the Veteran's claims for a compensable rating for bronchitis and chronic rhinitis as there was no evidence of record to support a finding that these conditions manifested to the level of a compensable rating during the period on appeal.

The Board denied service connection for hyperlipidemia, vitamin D deficiency, chronic bronchitis, irritable bowel syndrome, gastroesophageal reflux disease (GERD), hypertension, liver steatosis, and splenic artery aneurysm.

The Board denied the Veteran's claim for an initial rating more than 30 percent for asthma and chronic bronchitis, as the evidence did not support a higher rating.